NEW STUDY ON SHANK3
Also known as SH3, Shank3 is a protein that is found in synapses which allows neurons to pass on electrical signals from one neuron to another. This gene has been found to be associated with autism, language and speech disorders, and schizophrenia.
With this new study from MIT, scientists can also gain insight into the neurological mechanisms of the autism spectrum disorder. Using mice, they found that missing or defective Shank3 often causes compulsive behavior, avoidance of social interaction and anxiety. These are all similar behavior by human autistic patients.
Scientists genetically engineered the mice by turning off the Shank3 gene during embryonic development. They then added back the gene to young adult mice (two to four and a half months after being born) by feeding tamoxifen to mice.
Young adult mice did not project repetitive behavior or tendencies to avoid social interaction on this experiment, leading scientists believe that removing the gene during an early stage somehow reversed autism. At the cellular level, the team found that the density of dendritic spines dramatically increased in the striatum of treated mice, demonstrating the structural plasticity in the adult brain.
NOT OUT OF THE WOODS YET
Despite the revolutionary results of this study, Feng and his team discovered that the mice’s anxiety and some motor coordination issues still exist. The professor suspects that these behaviors probably rely on circuits that were irreversibly formed during early development.
They tried another angle, in which they returned the gene only 20 days after birth. The anxiety and motor coordination improved, so now they are working pinpointing the perfect time to intervene with the mice’s system.
“Some circuits are more plastic than others,” Feng says. “Once we understand which circuits control each behavior and understand what exactly changed at the structural level, we can study what leads to these permanent defects, and how we can prevent them from happening.”
THE FUTURE OF SHANK 3 INTERVENTION
Feng’s findings tell us that new genome-editing techniques can repair defective Shank3 gene to improve (if not eliminate) abnormalities such as autism, in theory. However, this technique is not ready to be tested on human patients yet.
The professor believes that scientists can find more general approaches to cater to human patients. An example is if we can identify defective circuits in autism patients, we can somehow modulate these circuits’ activity.
“That’s why it’s important in the future to identify what subtype of neurons are defective and what genes are expressed in these neurons, so we can use them as a target without affecting the whole brain,” Feng says.